Is BG Medicine Inc halal to invest in?

According to Musaffa's Shariah screening methodology, BG Medicine Inc (BGMD) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is BG Medicine Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes BG Medicine Inc using these criteria to determine its compliance status.

Can Muslims buy shares of BG Medicine Inc?

Muslim investors may consider investing in BG Medicine Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is BG Medicine Inc classified as NOT COVERED?

Musaffa determines the Shariah status of BG Medicine Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for BG Medicine Inc updated?

The Shariah compliance status of BG Medicine Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like BG Medicine Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of BG Medicine Inc?

You can check the latest Shariah compliance status of BG Medicine Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

BG Medicine Inc. Stock Analysis BGMD

United States Health Care Nano Cap

BG Medicine, Inc. is a life sciences company, which engages in the provision of developing and delivering innovative solutions for healthcare providers that provide insight and transform the clinical care of heart failure and related disorders. The company is headquartered in Waltham, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2011-02-04. The firm is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The firm's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The firm's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

Key Statistics of BG Medicine Inc (BGMD)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.00$0.00

Today's Open

$0.00

Volume

P/E Ratio (TTM)

52 Week Range

$0.00$0.00

Market Cap

11.40

Avg. Volume

Dividend Yield

Financial Metrics & Statements of BG Medicine Inc (BGMD)

FAQ's for BG Medicine Inc (BGMD)

According to Musaffa’s Shariah screening methodology, BG Medicine Inc (BGMD) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.